View Future GrowthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsTradeUP Acquisition 過去の業績過去 基準チェック /06TradeUP Acquisition は平均年間 14.7% の収益成長を遂げていますが、Capital Markets 業界では年間 収益成長率 となっています。6.3% です。主要情報14.73%収益成長率-20.10%EPS成長率Capital Markets 業界の成長10.26%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報30 Jun 2023最近の業績更新更新なしすべての更新を表示Recent updatesNew Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$2.8m). Revenue is less than US$1m. Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (US$16.9m market cap).お知らせ • May 17TradeUP Acquisition Corp. announced delayed 10-Q filingOn 05/16/2023, TradeUP Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 04Estrella Biopharma, Inc. entered into a definitive business combination agreement to acquire TradeUP Acquisition Corp. (NasdaqCM:UPTD) from TradeUP Acquisition Sponsor LLC and others for $32.3 million in a reverse merger transaction.Estrella Biopharma, Inc. entered into a definitive business combination agreement to acquire TradeUP Acquisition Corp. (NasdaqCM:UPTD) from TradeUP Acquisition Sponsor LLC and others for $32.3 million in a reverse merger transaction on September 30, 2022. Pursuant to the agreement, stockholders of Estrella immediately prior to the Effective Time collectively will receive from UPTD, in the aggregate, a number of newly issued shares of common stock of UPTD, equal to: (i) $325 million (the “ Merger Consideration ”), divided by (ii) $10.06 per share. The pro forma equity valuation (assuming no redemptions) of Estrella Immunopharma is expected to be approximately $398.5 million. Upon the closing of the transaction, TradeUP’s public stockholders would retain an ownership interest of approximately 11.1% in Estrella Immunopharma, the sponsors, officers, directors and other holders of TradeUP founder shares will retain an ownership interest of approximately 3.6% of Estrella Immunopharma, and the Estrella stockholders will own approximately 81.6% of Estrella Immunopharma. Upon closing of the transaction, Estrella shall become a publicly listed company and TradeUP will be renamed “Estrella Immunopharma, Inc.” Estrella’s President and Chief Executive Officer, Cheng Liu and the current management team will continue to lead Estrella Immunopharma. Cheng Liu will also continue in his role as President and Chief Executive Officer of Eureka. The board of directors of each of TradeUP and Estrella as well as stockholders of Estrella approved the transaction. The transaction will require the approval of the stockholders of TradeUP, the applicable waiting periods, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 having expired or terminated, the net tangible assets upon the consummation with the deal no less than $5,000,0001, the deal Consideration Shares having been approved for listing on Nasdaq, an aggregate of at least $20 million cash including (a) the amount of cash available in the Trust Account immediately prior to the Closing, completion of transaction financing prior to or at the closing of at least $20 million by UPTD and is subject to other customary closing conditions including the receipt of certain regulatory approvals. The deal is expected to close in the first half of 2023. Estimated cash proceeds to Estrella Immunopharma from the transaction are expected to consist of TradeUP’s approximately $45.4 million of cash in trust (assuming no redemptions). US Tiger Securities, Inc. has acted as financial advisor to TradeUP. Arila Zhou and Anna Jinhua Wang of Robinson & Cole LLP acted as legal advisor to TradeUP. Mike Blankenship, James Brown and Louis Savage of Winston & Strawn LLP acted as legal advisor to Estrella.収支内訳TradeUP Acquisition の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:UPTD 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費30 Jun 230-11031 Mar 230-11031 Dec 220-11030 Sep 220-11030 Jun 220-11031 Mar 220000質の高い収益: UPTDは現在利益が出ていません。利益率の向上: UPTDは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: UPTDは株式公開されてから 3 年未満しか経っていないため、過去 5 年間の前年比収益成長率がプラスであったかどうかを判断できません。成長の加速: UPTDの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: UPTDは利益が出ていないため、過去 1 年間の収益成長をCapital Markets業界 ( 37.2% ) と比較することは困難です。株主資本利益率高いROE: UPTDの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YDiversified-financials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/10/04 05:15終値2023/09/29 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋TradeUP Acquisition Corp. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$2.8m). Revenue is less than US$1m. Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (US$16.9m market cap).
お知らせ • May 17TradeUP Acquisition Corp. announced delayed 10-Q filingOn 05/16/2023, TradeUP Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 04Estrella Biopharma, Inc. entered into a definitive business combination agreement to acquire TradeUP Acquisition Corp. (NasdaqCM:UPTD) from TradeUP Acquisition Sponsor LLC and others for $32.3 million in a reverse merger transaction.Estrella Biopharma, Inc. entered into a definitive business combination agreement to acquire TradeUP Acquisition Corp. (NasdaqCM:UPTD) from TradeUP Acquisition Sponsor LLC and others for $32.3 million in a reverse merger transaction on September 30, 2022. Pursuant to the agreement, stockholders of Estrella immediately prior to the Effective Time collectively will receive from UPTD, in the aggregate, a number of newly issued shares of common stock of UPTD, equal to: (i) $325 million (the “ Merger Consideration ”), divided by (ii) $10.06 per share. The pro forma equity valuation (assuming no redemptions) of Estrella Immunopharma is expected to be approximately $398.5 million. Upon the closing of the transaction, TradeUP’s public stockholders would retain an ownership interest of approximately 11.1% in Estrella Immunopharma, the sponsors, officers, directors and other holders of TradeUP founder shares will retain an ownership interest of approximately 3.6% of Estrella Immunopharma, and the Estrella stockholders will own approximately 81.6% of Estrella Immunopharma. Upon closing of the transaction, Estrella shall become a publicly listed company and TradeUP will be renamed “Estrella Immunopharma, Inc.” Estrella’s President and Chief Executive Officer, Cheng Liu and the current management team will continue to lead Estrella Immunopharma. Cheng Liu will also continue in his role as President and Chief Executive Officer of Eureka. The board of directors of each of TradeUP and Estrella as well as stockholders of Estrella approved the transaction. The transaction will require the approval of the stockholders of TradeUP, the applicable waiting periods, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 having expired or terminated, the net tangible assets upon the consummation with the deal no less than $5,000,0001, the deal Consideration Shares having been approved for listing on Nasdaq, an aggregate of at least $20 million cash including (a) the amount of cash available in the Trust Account immediately prior to the Closing, completion of transaction financing prior to or at the closing of at least $20 million by UPTD and is subject to other customary closing conditions including the receipt of certain regulatory approvals. The deal is expected to close in the first half of 2023. Estimated cash proceeds to Estrella Immunopharma from the transaction are expected to consist of TradeUP’s approximately $45.4 million of cash in trust (assuming no redemptions). US Tiger Securities, Inc. has acted as financial advisor to TradeUP. Arila Zhou and Anna Jinhua Wang of Robinson & Cole LLP acted as legal advisor to TradeUP. Mike Blankenship, James Brown and Louis Savage of Winston & Strawn LLP acted as legal advisor to Estrella.